Twitter has officially launched its new video streaming service Periscope in direct opposition to the recently-introduced Meerkat service.Periscope was bought by Twitter earlier this year as it continues to develop... Read more
Pharma company UCB is part of a consortium which has won UK government funding to help develop next-generation approaches to manufacturing biologics.The UK government has awarded a £6.2 million grant... Read more
Several pharmaceutical companies have formed a coalition to help the UK government bring its 100,000 Genomes Project to fruition.Ten companies – including UK-based pharma majors AstraZeneca (AZ) and GlaxoSmithKline –... Read more
Bristol-Myers Squibb (BMS) has boosted its position in immunology research by licensing a portfolio of autoimmune disease therapies from Denmark's Novo Nordisk.The Danish drugmaker indicated last year that it intended... Read more
Latest Press Releases from the Global Pharma Showcase
EU’s Synergy Vision and US-based BoomCom to create global medical communications alliance
UK-based Synergy Vision, which has offices in London and Dublin, has formed an alliance with BoomCom in the US to provide clients with seamless communications strategy and programme implementation across Europe and the Americas. The expansion programme will see a truly global presence for the independently owned companies by the end of 2015, combining local knowledge with worldwide skills and resources.
Ffyona Dawber, Managing Director of Synergy Vision, comments “Importantly, the alliance enhances depth of resources and expertise offering global reach with tailored local programmes for clients to fit their needs.” Julie Busboom, founder and principal at BoomCom, notes “Since our inception in 1998, we have worked to deliver exceptional services to our clients. In Synergy Vision, we have found a partner that truly shares our core values.”
The agencies’ complementary values and a shared vision to develop and deliver medical communications programmes that really make a difference to healthcare professionals and patients set us apart in the global arena; as does our commitment to clients for consistent excellence and flexibility.
Med-comms focused Synergy Vision, which was PharmaTimes International Communications Agency Team of the Year 2014, offers clients an unparalleled synergy of relevant in-house pharma experience and solid medical communications know-how. To find out more please visit our website at http://www.synergy-vision.com/
BoomCom, based in Colorado, USA, is a medical communications group which combines scientific depth with creative communications to build and sustain brands. Their flexible and proactive approach offers clients a true partner. For more information please visit their website at http://www.boomcom.com/
Clients will continue to have a single, dedicated point of contact and one-stop billing, but will benefit from expanded expertise and experience when applicable to the brand.
UK’s Department of Health deploys information campaign to ensure continued vigilance over Ebola
The threat of Ebola being transmitted within the UK may be low but frontline health workers must remain vigilant nevertheless. This is the message being communicated by the Department of Health via, among other channels, the physician network Doctors.net.uk.
It is using the network’s ClinAlert service to drive its 20,000-strong UK GP community to information that highlights: • Five simple steps for GPs to follow if a patient presents with a suspected case of Ebola. • An updated infographic on the effect of the current outbreak of Ebola. Data for March 2015 reveals, among other things, that the total of global cases has reached 23,948.
GP members of Doctors.net.uk, comprising around half the country’s primary care community, receive news of the alert via a twice-weekly clinical bulletin tailored to each member’s profile. Dr Tim Ringrose, CEO of M3 Europe, the parent company of Doctors.net.uk, says “Communicating important information fast is imperative for good medical practice and we are proud that our community can be of service in this respect.”
Accompanying images to this release are available:
ClinAlert infographic on Ebola: click here Department of Health Ebola index page screen shot: click here
Zephyr Health aligns with Veeva on new approach to customer data that’s open and easy
San Francisco — March 24, 2015 –Zephyr Health, the only Data Intelligence solution built specifically for health science companies, today announced that it has joined the Veeva OpenKey Partner Program. Veeva OpenKey is a bold new approach to provide life sciences companies with customer data for healthcare professionals (HCP), healthcare organizations (HCO) and affiliations, and to do so with consistent standards for quality and service.
Zephyr Health customers, including Fortune 100 life science companies, use its unique technology to make more informed, strategic decisions when launching and managing their brands and products. Zephyr Health integrates thousands of global data sources into a single platform, and provides all-in-one applications for analysis and insight discovery.
“The Veeva OpenKey Partner Program makes it easy for life sciences companies to access and maximize customer data,” said Jason Wreath, vice president, Veeva OpenKey. “Today, companies’ ability to integrate and share data is hampered by restrictive vendor contracts. Data access agreements with partners like Zephyr Health eliminate those complications and make using customer data seamless and more cost-effective.”
“We provide data intelligence solutions to some of Veeva’s biggest customers,” said Ronald Meaux, vice president, products, Zephyr Health. “This partnership makes it easy to integrate Veeva OpenKey with our own data products and cloud-based software. As a result, our joint customers will spend less time and money getting the insights they need to bring new therapies to market.”
Digital Health Analytics Goes Mobile With Zephyr Health
Zephyr Health launches the first mobile analytics solution for health science companies, designed to bring field representatives and headquarters closer together
SAN FRANCISCO -- March 19, 2015 -- Zephyr Health, the only Data Intelligence solution built specifically for health sciences companies, today announced the launch of Voyager, a mobile analytics and primary feedback solution for healthcare and life science customers.
“Life science leaders need to get ahead of the massive amount of data rapidly transforming their current landscape,” said William King, founder and CEO, Zephyr Health. “Our solutions target commercial, medical and research leaders and put them in control of driving better business results, in addition to saving significant time and money. Now, with a single swipe, field and home office teams can benefit from synchronized and dynamic data capture, which means better communication and shared priorities.Ultimately, this results in getting the right treatments, to the right providers, to advance patient care faster than ever before.”
Voyager, the mobile extension of Zephyr Health’s powerful platform, automates the process of pushing insights to teams in the field and in turn, sends primary feedback to home office teams in real-time - no messy, disjointed spreadsheets. Now, sales representatives and medical science liaisons armed with an iPad will be able to validate target lists, analyze healthcare providers (HCPs) and institutions, and dynamically prioritize their activities, all in one mobile application.
Customers such as Gilead, Genentech and Medtronic utilize Zephyr Health’s Data Intelligence solutions to analyze the relationships between patients, healthcare providers and hospitals. Zephyr Health’s products bring together disparate data sources and use advanced analytics to filter, aggregate, organize and visualize meaningful insights - on demand. The company’s solutions include global data for every major disease and treatment area, plus the ability to add an organization's internal data for additional context. Strategic insights are easily discovered via pre-built software applications that are designed specifically for clinical, commercial and medical affairs teams.
“In health sciences, there’s a tremendous amount of data that remains largely disconnected. As a result, the enterprise software market is littered with complicated products that business people struggle to use,” said Ronald Meaux, vice president, products, Zephyr Health. “Voyager provides a consumer-grade design that makes it easy for business people to use and enjoy. It’s designed to be as elegant and self-evident as the iPad itself.”
Zephyr Health integrates thousands of global data sources into a single platform, and provides all-in-one applications for analysis and insight discovery. Voyager is designed to complement mobile CRM applications already in use by sales representatives and medical science liaisons. The goal is not to build a new transaction system, but rather to increase the value of those investments already made by Zephyr Health’s customers.
Voyager Key Benefits:
Find new insights: Experience powerful targeting for enhanced prioritization and profiling of key target healthcare professionals
Improve strategic planning: Complete synchronization between home office and field staff for better communication and shared priorities with the push of a button; No consultants or IT staff required
Better territory management: Real-time visibility into accurate, current information about health care professionals and institutions for more meaningful interactions
Instant market validation: Automatically determine targets and complete surveys questions with a click so that you can get the right message to the marketplace faster
Reduce costs: Zephyr Health takes care of the complicated software, data feeds, analysis and dashboards so that you and your teams can focus on a common view of advocacy initiative outcomes
Founded in 2011 by William King, Zephyr Health has created the only Data Intelligence solution built specifically for pharmaceutical, biotech, diagnostics and medical device companies. Our all-in-one solution connects and organizes multiple data sources – private and public – into visual applications for real-world business outcomes so that our customers can better connect their therapies to the people who need them the most. Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK and Pune, India. Zephyr Health is venture backed by Kleiner Perkins Caufield & Byers and Icon Ventures. For more information, please visit:www.zephyrhealth.com.
Veeva Systems has launched Veeva OpenKey, a new type of customer data solution for the life sciences industry. As the life sciences business continues to diversify across borders and new channels, the need for easily accessible and accurate HCO, HCP and affiliations information has never been greater. Yet many companies are still hindered by poor internal data sharing processes and restrictive agreements with external data providers.
Veeva Systems Introduces Veeva OpenKey
Veeva Unveils a New Approach to Customer Reference Data that’s Open, Easy, and Global
Ecosystem of Veeva OpenKey Partners Align to Make Using Customer Data
Seamless and Cost-Effective
BARCELONA, SPAIN – 24 March, 2015– On opening day of eyeforpharma Barcelona 2015, Veeva Systems (NYSE: VEEV) announced Veeva OpenKey, a new approach to customer reference data for the life sciences industry. Veeva OpenKey builds on Veeva’s growing presence in the data business with a bold vision to provide customer data for all healthcare professionals (HCP), healthcare organisations (HCO), and affiliations across life sciences’ major markets—and to do so with consistent standards for quality and service.
Veeva also announced the Veeva OpenKey Partner Program, which establishes a partner ecosystem designed to make it easy for life sciences companies to access and maximise their customer data. Today, companies’ ability to fully leverage the customer data they purchase is hampered by restrictive vendor contracts that limit usage and access. With data access agreements and partnerships in place with other third-party providers, Veeva OpenKey eliminates those complications.
“Veeva is dedicated to solving the customer data challenges for life sciences organisations, with a customer-first approach to quality and service,” said Tim Slevin, senior vice president of Veeva’s global data solutions business. “This starts with freeing companies of the constraints preventing them from reaping the full benefits of their customer data and our commitment to deliver an offering that provides truly global support.”
Survey Reveals Need for Data That is Open, Easy, and Global
Currently, 83 percent of life sciences executives surveyed report the quality of their customer data is a significant challenge, according to preliminary results of the Veeva 2015 European Life Sciences Industry Survey on Customer Data.[i] More than one in four say they are dissatisfied with the service they receive from their current data provider, and just 12 percent say incumbent providers have innovated to deliver high-quality data solutions.[ii]
Veeva OpenKey will provide a faster, more responsive service with a consistently high standard for quality across regions. Veeva OpenKey will make it easy for companies to use the data they need—wherever, whenever, and however they need it, without the burdensome contractual restrictions that exist in the customer data market today. And its fair, simple pricing is free of complicated conditions or surprises.
In the face of changing regulations and more stringent reporting requirements, the need for consistent, cross-border customer data has never been more acute. Less than a year away from the January 2016 European Federation of Pharmaceutical Industries and Associations’ (EFPIA) payment disclosure deadline, only 39 percent of companies surveyed definitively report that their customer data allows them to accurately track or aggregate spend at the HCP level.[iii] And only 29 percent have data that fully allows them to manage HCP engagement activity across regional or country borders.[iv]
To eliminate the burden of managing multiple data feeds and duplication of HCP and HCO records across European markets Veeva OpenKey Customer Data will be sourced locally and consolidated into a single global reference database.
"Life sciences companies struggle to maintain timely, complete customer data across their internal systems, resulting in significant compliance and customer engagement challenges,” said Eric Newmark, program director, Business Systems Strategies for IDC Health Insights. “Much of the challenge stems from their inability to integrate and fully utilise the data they purchase today. More open access to quality data and partner ecosystems that work together to ensure access is seamless for customers is something the industry desperately needs."
“We are proud to partner with Veeva as they continue their journey towards a vision of providing the most comprehensive data and service solutions for the life sciences industry,” said Robert Bryant, Partner at Deloitte. “We have worked with Veeva on early Veeva OpenKey customers and have been impressed with the solution and vision.”
About Veeva OpenKey
Central to the Veeva OpenKey data and services offerings is Veeva OpenKey Customer Data, which includes records for millions of HCP, HCO, and affiliations. Customer records are continuously updated from authoritative industry sources for the best, most timely information, including digital profile data crucial to today’s multichannel engagement. The highest standards of quality and completeness are ensured through rigorous, automated, and steward-led validation. Veeva also provides a range of data maintenance services including cleansing, enhancement, and validation.
To help the industry realise greater value from customer data, a large and growing contingent of organisations have already become Veeva OpenKey partners, including Axtria, BMI SYSTEM, Crossix Solutions, Decision Resources Group, LiquidHub, OpenQ, Symphony Health Solutions, Qlik, and Zephyr Health.
Veeva OpenKey Customer Data and services are currently available in Australia, China, the United Kingdom, and the United States. Availability for other major European countries is expected in 2015, with other regions to follow in 2016.
About Veeva Systems Veeva Systems Inc. is a leader in cloud-based software for the globallife sciences industry. Committed to innovation, product excellence,and customer success, Veeva has more than 275 customers, ranging from theworld's largest pharmaceutical companies to emerging biotechs. Veevais headquartered in the San Francisco Bay Area, with offices inEurope, Asia, and Latin America. For more information, visitwww.veeva.com.
Forward-looking Statements This release contains forward-looking statements, including the market demand for and acceptance of the Veeva OpenKey data products and related services, plans for expanding the geographic coverage of the Veeva OpenKey data products and related services, the results from use of the Veeva OpenKey data products and related services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2014, which is available on the company’s web site at www.veeva.com under the Investors section and on the SEC’s website at www.sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
[i]Veeva Systems, “European Life Sciences Industry Survey on Customer Data, Summary of Preliminary Results,” March 2015.